About Uteron Pharma
Uteron Pharma is a company based in Liege (Belgium) founded in 2002 by Jean Michel Foidart and Stijn Van Rompay was acquired by Teva Pharmaceuticals in January 2013. It operates as a B2B. Uteron Pharma has raised $31.09 million across 3 funding rounds from investors including Teva Pharmaceuticals, Nomainvest and Saffelberg Investments. Uteron Pharma operates in a competitive market with competitors including Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others.
- Headquarter Liege, Belgium
- Founders Jean Michel Foidart, Stijn Van Rompay
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31.09 M (USD)
in 3 rounds
-
Latest Funding Round
$18.68 M (USD), Series B
Mar 28, 2012
-
Investors
Teva Pharmaceuticals
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Teva Pharmaceuticals
(Jan 23, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Uteron Pharma
Uteron Pharma has successfully raised a total of $31.09M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18.68 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $18.7M
-
First Round
First Round
(04 May 2011)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2012 | Amount | Series B - Uteron Pharma | Valuation |
investors |
|
| Sep, 2011 | Amount | Series A - Uteron Pharma | Valuation |
investors |
|
| May, 2011 | Amount | Series A - Uteron Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Uteron Pharma
Uteron Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Teva Pharmaceuticals, Nomainvest and Saffelberg Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Buyouts are pursued by SRIW as a private equity firm.
|
Founded Year | Domain | Location | |
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Uteron Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Uteron Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Uteron Pharma Comparisons
Competitors of Uteron Pharma
Uteron Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
A next-generation suction-based cervical device for gynecology is provided.
|
|
| domain | founded_year | HQ Location |
Medical devices for women's healthcare are developed and provided.
|
|
| domain | founded_year | HQ Location |
Transcervical sterilization systems for permanent birth control are developed.
|
|
| domain | founded_year | HQ Location |
Medical devices for subdermal implant removal are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Uteron Pharma
Frequently Asked Questions about Uteron Pharma
When was Uteron Pharma founded?
Uteron Pharma was founded in 2002 and raised its 1st funding round 9 years after it was founded.
Where is Uteron Pharma located?
Uteron Pharma is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Is Uteron Pharma a funded company?
Uteron Pharma is a funded company, having raised a total of $31.09M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10.37M, raised on May 04, 2011.
What does Uteron Pharma do?
Uteron Pharma develops products dedicated to female healthcare solutions through providing healthcare solutions, producing pharmaceutical products, womens health, and developing products. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Who are the top competitors of Uteron Pharma?
Uteron Pharma's top competitors include Daré Bioscience, Femasys and Aspivix.
Who are Uteron Pharma's investors?
Uteron Pharma has 6 investors. Key investors include Teva Pharmaceuticals, Nomainvest, Saffelberg Investments, SRIW, and Noshaq.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.